Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

Early radiologic and metabolic tumour response assessment during combined chemo-radiotherapy for locally advanced NSCLC

“…Patient selection and eligibility are currently based on clinical baseline data such as stage and performance status (PS). However, several studies have suggested that early radiologic (CT-based) and metabolic (positron emission tomography (PET)-based) response to treatment might add predictive value, and a variety of metrics at different timepoints of the treatment course have been investigated [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] . Unfortunately, most studies are limited by small patient numbers, different timepoints of measuring response, incompatible endpoints, and conflicting results.…”